Colonial Tournament Defending Champion Steve Flesch Educates Texans about Sun Exposure and Skin Health

Tee Off Against AKs Campaign Brings Free Skin Cancer Screenings to the Bank of America Colonial Golf Tournament

Fort Worth, TX — May 16, 2005 — Two-time PGA TOUR winner Steve Flesch is teaming up with Dermik Laboratories to host the Tee Off Against AKs Campaign at the 2005 Bank of America Colonial Golf Tournament. Tee Off Against AKs is a public awareness campaign designed to educate the golf community about actinic keratoses (AKs) – pre-cancerous skin lesions – and the need for proper skin protection. In 2002, Flesch, defending Colonial Golf Tournament champion, was diagnosed with AKs, as a result of years of sun exposure, and received treatment from his dermatologist.

"Like most golfers, I was more focused on my swing than my skin. Given the amount of time I spend outdoors, I was fortunate that my AKs were detected and treated before they led to skin cancer," said Steve Flesch, PGA TOUR golfer. "My doctor prescribed Carac® (fluorouracil cream) Cream, 0.5%, which worked for me. Now, I take the proper steps to protect my skin from the dangers of prolonged sun exposure. I apply sunscreen, wear a hat and see my dermatologist regularly." During the Bank of America Colonial Golf Tournament, which takes place from May 16 – May 22, 2005 at the Colonial Country Club, Fort Worth, Flesch will be joined by local board-certified dermatologists, who will provide event participants and spectators with free skin cancer screenings. Consumers will also have an opportunity to have their photo taken with a special UV-camera that will show the extent of existing sun damage on their face at the Carac® sponsorship tent.

Patrons can also pick up a free Tee Off Against AKs silicone bracelet at the tent to show their support for this campaign aimed at raising awareness about this precancerous condition. "Golf enthusiasts are especially at risk for actinic keratosis due to the increased sun exposure they receive on vulnerable body parts, like the face, forearms, and back of the hands," said Perry Robins, MD, President, Skin Cancer Foundation. "Prolonged sun exposure is dangerous to the skin; therefore it is important for people to get routinely checked for skin problems."

Flesch will appear at the Carac® sponsorship tent on Wednesday, May 18, 2005, to share his personal experience battling AKs. In addition, free skin cancer screenings will be offered on the following dates and times: Wednesday, May 18, 10 a.m. – 4 p.m.; Thursday, May 19, 10 a.m.-4p.m.; Friday, May 20, 10 a.m. – 4 p.m., Saturday, May 21, 10 a.m. – 4 p.m.; Sunday, May 22, 10 a.m. – 4 p.m. AKs are lesions that typically occur on the face, scalp, forearms, or back of hands. AKs begin under the skin's surface, then often emerge as rough or scaly areas that may feel like sandpaper to the touch. They can be tan, red or the same color as skin. People aged 40 and over who have had chronic sun exposure or a history of repeated sunburns, and burn rather than tan in the sun, and those who spend large amounts of time in the sun without sunscreen are at higher risk for AKs.

About Carac®
Carac® (fluorouracil cream) Cream, 0.5% is a once-a-day, topical treatment for actinic keratosis of the face and anterior scalp that has been approved by the U.S. Food and Drug Administration. Carac® provides patients with an effective AK treatment with the benefit of convenient once-daily dosing.

Carac® should not be used by women who are pregnant, considering becoming pregnant, or nursing. Carac® should not be used by people with dihydropyrimidine dehydrogenase (DPD) enzyme deficiency. The most common side effects are skin reactions including redness, dryness, burning, pain, erosion (loss of upper layer of skin), swelling and eye irritation.

About Dermik Laboratories
Carac® is marketed by Dermik Laboratories. Dermik Laboratories conducts the North American business of sanofi-aventis Dermatology, the global dermatology unit of sanofi-aventis. Dermik Laboratories has nearly 60 years of experience in the development, marketing and distribution of innovative prescription pharmaceutical products.

Dermik has created a new division, Dermik Aesthetics, that will focus on marketing innovative, enduring and reliable treatments to improve appearance and well being. Dermik's mission is to foster healthy-looking skin and in turn, a healthy outlook for life.

About sanofi-aventis
The sanofi-aventis Group is the world's third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine and vaccines. The sanofi-aventis Group is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). The sanofi-aventis Group conducts business in the U.S. through its subsidiaries Sanofi-Synthelabo Inc. and Aventis Pharmaceuticals Inc.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. The statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expect", "anticipates", "believes", "intends", "estimates"
and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward looking information and statements. These risks and uncertainties include those discussed or identified in the public filing with the SEC and the AMF made by sanofi-aventis and Aventis, including those listed under "Forward-Looking Statements" and "Risk Factors" in the sanofi-aventis's annual report on Form 20-F
for the year ending December 31, 2003 and those listed under "Cautionary Statement Regarding Forward-Looking Statements" and "Risk Factors" in Aventis's annual report on Form F-20 for the year ending December 31, 2003. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.